Search Orphan Drug Designations and Approvals
-
Generic Name: | Octreotide | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Sandostatin LAR | ||||||||||||||||
Date Designated: | 08/24/1998 | ||||||||||||||||
Orphan Designation: | Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors. | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, New Jersey 07936 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | Octreotide |
---|---|---|
Trade Name: | Sandostatin LAR | |
Marketing Approval Date: | 11/25/1998 | |
Approved Labeled Indication: | Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome. | |
Exclusivity End Date: | 11/25/2005 | |
Exclusivity Protected Indication* : | ||
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-